Amedisys (NASDAQ:AMED) Price Target Increased to $150.00 by Analysts at Oppenheimer

Amedisys (NASDAQ:AMED) had its price target boosted by stock analysts at Oppenheimer from $140.00 to $150.00 in a research report issued to clients and investors on Thursday, The Fly reports. Oppenheimer’s price objective indicates a potential upside of 11.10% from the stock’s current price.

A number of other brokerages have also recently commented on AMED. BidaskClub upgraded Amedisys from a “buy” rating to a “strong-buy” rating in a report on Friday, July 26th. Raymond James raised their target price on Amedisys from $140.00 to $144.00 and gave the company an “outperform” rating in a report on Monday, July 15th. ValuEngine upgraded Amedisys from a “hold” rating to a “buy” rating in a report on Saturday, June 22nd. Finally, Jefferies Financial Group set a $150.00 target price on Amedisys and gave the company a “buy” rating in a report on Monday, July 8th. Seven analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. Amedisys has a consensus rating of “Buy” and an average target price of $135.55.

Shares of NASDAQ:AMED traded down $0.05 during midday trading on Thursday, reaching $135.01. 419,435 shares of the company’s stock were exchanged, compared to its average volume of 326,002. The stock has a 50 day moving average price of $124.99. The company has a current ratio of 0.91, a quick ratio of 0.91 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $4.42 billion, a PE ratio of 37.19, a price-to-earnings-growth ratio of 1.71 and a beta of 1.41. Amedisys has a fifty-two week low of $97.38 and a fifty-two week high of $141.98.

Amedisys (NASDAQ:AMED) last issued its quarterly earnings data on Wednesday, July 31st. The health services provider reported $1.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.24. The firm had revenue of $492.98 million during the quarter, compared to the consensus estimate of $489.66 million. Amedisys had a return on equity of 28.36% and a net margin of 6.84%. The company’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period last year, the company earned $1.00 EPS. On average, analysts expect that Amedisys will post 4.09 EPS for the current year.

In related news, insider Michael Paul North sold 1,183 shares of the firm’s stock in a transaction dated Thursday, July 18th. The stock was sold at an average price of $130.00, for a total transaction of $153,790.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider David L. Kemmerly sold 5,000 shares of the firm’s stock in a transaction dated Monday, May 20th. The shares were sold at an average price of $109.96, for a total value of $549,800.00. The disclosure for this sale can be found here. Insiders have sold a total of 56,278 shares of company stock valued at $6,673,207 over the last 90 days. 2.90% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently made changes to their positions in the company. Alpha Quant Advisors LLC boosted its stake in shares of Amedisys by 137.0% in the 1st quarter. Alpha Quant Advisors LLC now owns 237 shares of the health services provider’s stock valued at $29,000 after buying an additional 137 shares during the period. CWM LLC boosted its stake in shares of Amedisys by 482.2% in the 2nd quarter. CWM LLC now owns 262 shares of the health services provider’s stock valued at $32,000 after buying an additional 217 shares during the period. Tompkins Financial Corp purchased a new position in shares of Amedisys in the 2nd quarter valued at about $37,000. NEXT Financial Group Inc purchased a new position in shares of Amedisys in the 2nd quarter valued at about $82,000. Finally, Meeder Asset Management Inc. boosted its stake in shares of Amedisys by 102.3% in the 1st quarter. Meeder Asset Management Inc. now owns 965 shares of the health services provider’s stock valued at $120,000 after buying an additional 488 shares during the period. Institutional investors and hedge funds own 88.10% of the company’s stock.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and Personal Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses, physical and speech therapists, occupational therapists, social workers, and aides for its patients to complete their important personal tasks.

Further Reading: What does a neutral rating on stocks mean?

The Fly

Analyst Recommendations for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.